arrow
G

Guillaume Cartron

centre hospitalier universitaire de montpellier
H指数:68
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling

CD200是一种依赖于IGF1受体信号传导的多发性骨髓瘤新型强效生长因子

2026-08-280
OAAI
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study

CAR T细胞疗法期间复发/难治性弥漫大B细胞淋巴瘤的标准化FDG-PET解读:一项DESCAR-T研究

2026-07-250
PRE
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

Englumafusp alfa联合glofitamab治疗b 细胞非霍奇金淋巴瘤: 1期试验

2026-07-160
OAAI
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL

利萨库特根马拉鲁赛尔在3L+ FL中的持久疗效和可管理的长期安全性:TRANSCEND FL研究3年更新

Blood
IF23.1
2026-07-030
OA
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm

短时间爬坡剂量的 glofitamab 在抗CD19 CAR T细胞疗法失败后,可降低弥漫性大B细胞淋巴瘤患者的死亡风险:具有预设外部对照臂的LYSA BiCAR II期试验的最终结果

2026-07-010
OAAI
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL

患者来源的淋巴瘤球体揭示了Glofitamab耐药性的预测标志物在复发/难治性B-NHL中

Blood
IF23.1
2026-03-020
PRE
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma
2026-01-130
OAAI
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma

合成致死组合:DNA修复抑制剂与基因毒性剂的联用,靶向高风险弥漫性大B细胞淋巴瘤

2025-08-230
OAAI
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study

Brentuximab Vedotin联合Gemcitabine治疗复发或难治性外周T细胞淋巴瘤:一项LYSA II期研究

2025-08-060
OAAI
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的骨髓瘤患者不良预后相关

2025-07-200
OA
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Glofitamab在难治性或复发性弥漫性大B细胞淋巴瘤中的应用:一项在CAR-T细胞疗法失败后的II期LYSA研究

2025-04-030
PRE
Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction

Ironomycin通过靶向铁代谢依赖性诱导套细胞淋巴瘤细胞死亡

2025-02-030
OA
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Camus, V.; Molina, T.J.; Desmots, F.; Blanc-Durand, P.; Kanoun, S.; Moslemi, A.; Ruminy, P.; Le Gouill, S.; Ghesquieres, H.; Obéric, L.; et al. 4个周期后的中期PET预测组织分子学确诊的原发性纵隔B细胞淋巴瘤的结局。Blood Adv. 2025, 9, 2232–2246. [Google Scholar] [CrossRef] [PubMed]

2025-01-010
OAAI